Naringenin restores osteogenic differentiation in TNF-α-Treated bone marrow mesenchymal stem cells by targeting AKR1B1

Le résumé fourni par la source

In chronic inflammatory microenvironments, TNF-α disrupts bone remodeling by suppressing osteogenic differentiation in human bone marrow mesenchymal stem cells (hBMSCs), while conventional TNF-α inhibitors lack osteoprotective effects. This study reveals that naringenin counteracts TNF-α-induced osteogenic suppression by potentially targeting AKR1B1 to restore redox balance and inhibit NF-κB-mediated inflammation. In vitro experiments demonstrated that naringenin restored osteogenic capacity in TNF-α-treated hBMSCs, enhancing ALP activity, mineralization, and expression of RUNX2/OCN while reducing IL-6/IL-1β levels. Mechanistically, naringenin scavenged free radicals, elevated SOD/CAT activity, and attenuated TNF-α-driven ROS accumulation. Bioinformatics analysis identified TNF-α-activated NF-κB signaling and upregulation of the oxidative stress enzyme AKR1B1, with molecular docking confirming strong binding between naringenin and AKR1B1. This study pioneers AKR1B1 as a novel therapeutic target for inflammatory bone loss, demonstrating naringenin's synergistic "antioxidant-anti-inflammatory-pro-osteogenic" effects. These findings provide a theoretical foundation for phytochemical applications in orthopedic therapies and highlight potential clinical translation strategies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.